Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK2 over exp | Advanced Solid Tumor | sensitive | Ruxolitinib + ZSTK474 | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790). | 24251790 | |
JAK2 over exp | Advanced Solid Tumor | sensitive | Pictilisib + Ruxolitinib | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790). | 24251790 | |
JAK2 over exp | Advanced Solid Tumor | sensitive | Dactolisib + Ruxolitinib | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790). | 24251790 | |
JAK2 over exp | Advanced Solid Tumor | sensitive | Ruxolitinib + TGX-221 | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790). | 24251790 | |
JAK2 over exp | triple-receptor negative breast cancer | sensitive | NVP-BSK805 + Paclitaxel | Preclinical - Pdx | Actionable | In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627). | 27075627 |